LOC647104 Inhibitors

LY294002 and Wortmannin are both inhibitors of PI3K, a lipid kinase that initiates the AKT pathway, crucial for cell survival and growth. PD98059 and U0126 target MEK enzymes, which are pivotal in the ERK/MAPK pathway, involved in cell proliferation and differentiation. Inhibition of these kinases can suppress the activation of downstream components that might intersect with LOC647104's role in the cell. JNK and p38 MAPK are targets of SP600125 and SB203580, respectively. These kinases participate in stress response pathways, which can lead to alterations in cell death and inflammation, processes that LOC647104 may influence. MG132's inhibition of the proteasome can disrupt protein degradation, potentially affecting protein levels that interact with or modulate LOC647104.

Dasatinib and PP2 are inhibitors of Src family kinases and the Abl kinase, which are involved in regulating various cellular processes including adhesion, migration, and proliferation, potentially intersecting with LOC647104's function. Gefitinib targets the EGFR kinase, a key player in cell growth and apoptosis pathways. Rapamycin's inhibition of mTOR can lead to changes in cell growth and metabolism, which are important processes that LOC647104 might be associated with. Lastly, 2-Methoxyestradiol disrupts HIF-1α, involved in hypoxic responses, and microtubule dynamics, which can lead to cell cycle arrest and affect angiogenesis.